CAUSAL INFERENCE · STATISTICAL ROBUSTNESS · FIRST AUTHOR

Causal inference, measurement, and research leadership.

“GWAS advancements to investigate disease associations and biological mechanisms”

Clinical and Translational Discovery · Volume 4, Issue 3 · e296 · First published 1 May 2024

01 / QUANTITATIVE METHODS

Methods for separating association from evidence of causation.

The article reviews instrumental-variable and Mendelian-randomization approaches, robustness estimators, bias mechanisms, and measurement technologies used across disease-association research.

01

Instrumental variables

Two-stage least squares and related designs for estimating causal effects from observational evidence.

02

Robustness estimators

Inverse-variance weighting, Egger regression, Bayesian methods, mixture models, and block jackknife resampling.

03

Bias mechanisms

Confounding, reverse causation, multiple testing, and overlapping-sample contamination.

04

Measurement trade-offs

Coverage, sensitivity, and cost comparisons across sequencing, array-based, and lower-coverage technologies.

02 / LEADERSHIP & AUTHORSHIP

Research leadership across disciplines.

At Rutgers Institute for Health, I directed a seven-member team spanning bioscience, software, project management, and pre-med research contributors.

7team members led
150+studies synthesized
1stauthor position
2025Top Viewed recognition

My role included setting the research scope, dividing technical work across disciplines, reviewing contributions, controlling the final analytical standard, and leading manuscript revision through acceptance.

The work required comparing estimators, identifying failure modes in observational inference, reconciling evidence across more than 150 studies, and communicating technical conclusions for expert review.

03 / CITATION
Omidiran, O., Patel, A., Usman, S., Mhatre, I., Abdelhalim, H., DeGroat, W., Narayanan, R., Singh, K., Mendhe, D., & Ahmed, Z. (2024). “GWAS advancements to investigate disease associations and biological mechanisms.” Clinical and Translational Discovery, 4(3), e296. https://doi.org/10.1002/ctd2.296
VIEW QUANTITATIVE RESEARCHEquity Volatility Research Pipeline